A comprehensive analysis of Lymphoma‐associated haemophagocytic syndrome in a large French multicentre cohort detects some clues to improve prognosis. (24th July 2018)

• Record Type: Journal Article
• Authors: Bigenwald, Camille; Fardet, Laurence; Coppo, Paul; Meignin, Véronique; Lazure, Thierry; Fabiani, Bettina; Kohn, Milena; Oksenhendler, Eric; Boutboul, David; Uzzan, Mathieu; Lambotte, Olivier; Galicier, Lionel
• Is Part Of: British journal of haematology. Volume 183:Number 1(2018)
• Page Start: 68
• Page End: 75
• Publication Date: 2018-07-24
• Subjects: lymphoma -- haemophagocytic syndrome -- human herpes virus 8 -- human immunodeficiency virus; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.15506
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: Lymphoma‐associated haemophagocytic syndrome (LAHS) accounts for most cases of secondary haemophagocytic syndrome (HS) and has been extensively described in Asian populations. However, little is known about the epidemiology of LAHS in Western countries. We herein report a case series of 71 LAHS patients in which the lymphomas were mainly of the aggressive type. Diagnoses included non‐Hodgkin B cell lymphoma (46·5%) including human herpes virus 8‐associated non‐Hodgkin lymphoma (12·7%), T cell lymphoma (28·2%) and Hodgkin lymphoma (23·9%). An underlying immunodeficiency was described in 30 patients (42·3%). Early mortality within the 30 days following HS diagnosis was observed in 26·8% of cases. The overall survival was estimated at 45·7% [95% confidence interval, CI (35·4–59·0)] at 6 months, and 34·3% [95% CI (24·8–47·4)] at 2 years. Concurrent infection, age over 50 years, ethnicity and etoposide treatment were independently associated with mortality. While it appears that certain types of lymphomas were more prone to trigger HS, LAHS were not restricted to a few types of lymphoma. The overall prognosis was poor, with a particularly high rate of early mortality, highlighting the importance of both early recognition and choice of initial therapeutic management.